ELVIRA DEOLINDA RODRIGUES PEREIRA VELLOSO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
- Long Term Outcomes of Adult Lymphoblastic Lymphoma Patients Treated with Pediatric Regimen in Brazil(2021) MAIA, Ana Carolina Arrais; SILVA, Wellington F.; VELLOSO, Elvira; REGO, Eduardo M.; PEREIRA, Juliana; ROCHA, Vanderson
- Cytogenetic studies for cMYC, BCL2 and BCL6 genes in neoplasm: comparison of karyotype, FISH in paraffin-embedded tissue and FISH in methanol-acetic acid-fixed cells suspensions(2021) GARCIA, Caroline Henriques; SILVA, Roberta Maria da; SAFRANAUSKAS, Oliveira; BEZERRA, Alanna Mara P. S.; VELLOSO, Elvira D. R. P.
- Assessing the Impact of Prophylactic Anidulafungin during Remission Induction of Acute Myeloid Leukemia - a Propensity-Score Matching Analysis(2021) SILVA, Wellington F.; MENDES, Fernanda Rodrigues; MELO, Raphael Bandeira; VELLOSO, Elvira; ROCHA, Vanderson; REGO, Eduardo M.
- Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort(2021) SILVA, Wellington F.; SILVERIO, Alexandre; DUARTE, Bruno Kosa Lino; AGUIAR, Thais Ferraz; BENDLIN, Rodrigo Miguel; MASSAUT, Ires Hamyra Bezerra; PAGNANO, Katia Borgia Barbosa; VELLOSO, Elvira D. R. P.; ROCHA, Vanderson; REGO, Eduardo MagalhaesOutside of clinical trials, few studies have addressed the outcomes of Ph+ acute lymphoblastic leukemia (ALL) in adults, especially from developing world. In this study, we conducted a multicenter analysis on the outcomes of patients aged > 15 years with Ph+ ALL, aiming to get to know an overview of the Brazilian experience as well as to explore baseline factors associated with relapse and mortality in our setting. Over these 10 years, patients were treated with diverse protocols, all of them always combined with a frontline tyrosine-kinase inhibitor. A total of 123 Ph+ ALL patients was included. Imatinib was the first line TKI in 97 %. The complete response rate was 79 %. The early death rate was 15 %, being associated with increasing age at diagnosis (p = 0.06). The use of intensive versus attenuated induction regimen was not associated with higher induction mortality (p = 0.99). Overall, 29 % of patients aged <= 60 years underwent allogeneic transplantation, 87 % in first CR. 4-year overall survival (OS) and relapse-free survival were 25 % and 24 %, respectively. The incidence of relapse (death as a competitor) was 29 %, while the non-relapse mortality was 42 %. Only age was independently associated with OS, and lactate dehydrogenase level and central nervous disease at diagnosis were related to relapse in our cohort. This is the first historical cohort multicenter study on Ph+ ALL from Brazil. Reporting these outcomes is essential to encourage public policies to expand access to new drugs and transplantation in middle-income countries.
- A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?(2021) SILVEIRA, Douglas R. A.; COELHO-SILVA, Juan L.; SILVA, Wellington F.; VALLANCE, Grant; PEREIRA-MARTINS, Diego A.; MADEIRA, Maria I. A.; FIGUEREDO-PONTES, Lorena L.; VELLOSO, Elvira D. R. P.; SIMOES, Belinda P.; PENIKET, Andy; DANBY, Robert; REGO, Eduardo M.; VYAS, Paresh; TRAINA, Fabiola; BENDIT, Israel; QUEK, Lynn; ROCHA, VandersonOutcomes in acute myeloid leukemia (AML) are dependent on patient- and disease-characteristics, treatment, and socioeconomic factors. AML outcomes between resource-constrained and developed countries have not been compared directly. We analyzed two cohorts: from Sao Paulo state, Brazil (USP,n = 312) and Oxford, United Kingdom (OUH,n = 158). USP cohort had inferior 5-year overall survival compared with OUH (29% vs. 49%, adjusted-p=.027). USP patients have higher early-mortality (23% vs. 6%p<.001) primarily due to multi-resistant Gram-negative bacterial and fungal infections. USP had higher 5-year cumulative incidence of relapse (60% vs. 50%,p=.0022), were less likely to undergo hematopoietic stem cell transplant (HSCT) (28% vs. 75%,p<.001) and waited longer for HSCT (median, 23.8 vs. 7.2 months,p<.001). Three-year survival in relapsed patients was worse in USP than OUH (10% vs. 39%,p<.001). Our study indicates that efforts to improve AML outcomes in Brazil should focus on infection prevention and control, and access to HSCT.
- Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients(2021) GONZALEZ, Jacqueline S.; PERUSINI, Maria Agustina; BASQUIERA, Ana L.; ALFONSO, Graciela; FANTL, Dorotea; LIMA, Walter Macedo; NUCIFORA, Elsa; LAZZARINO, Carolina; NOVOA, Viviana; SILVA, Marcela Cavalcanti de Andrade; LARRIPA, Irene B.; ROCHA, Vanderson; ARBELBIDE, Jorge; VELLOSO, Elvira D. R. P.; BELLI, Carolina B.Knowledge on chronic myelomonocytic leukemia (CMML) patients from Argentina and Brazil is limited. Our series of 280 patients depicted an older age at diagnosis (median 72 years old), 26% of aberrant karyotypes, and a prevalence of myelodysplastic (60%) and CMML-0 subtypes (56%). The median overall survival (OS) was 48.2 months for patients in CMML-0 (Ref.), 24.7 months for those in CMML-1 (HR = 2.0, p = 0.001), and 8.8 months for patients in CMML-2 (HR = 4.6, p < 0.001). In the CMML-0 category, median OS were different between myelodysplastic and myeloproliferative subtypes (63.7 vs 21.2 months, p < 0.001); however, no differences were observed within CMML-1 and CMML-2 subtypes (24.7 vs 23.7 months, p = 0.540, and 9.1 vs 8.2 months, p = 0.160). The prognostic impact of 24 variables and 7 prognostic systems was adjusted to the WHO 2016 after validating their usefulness. Multivariate analysis were performed, and the final model revealed Hb >= 8 -< 10g/dL (HR 1.7), Hb < 8g/dL (HR 2.8), poor karyotypes (HR 2.1), WHO 2016-CMML-1 (HR 2.1), and CMML-2 (HR 3.5) as independent adverse clinical parameters in our cohort with a borderline influence of platelets count < 50 x 10(9)/L (HR 1.4). We could validate several scoring systems, the WHO 2016 proposal and its prognostic capability, along with accessible covariates, on predicting the outcome in our series of CMML patients from Latin America.
- The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy(2021) HOMAN, Claire C.; KING-SMITH, Sarah L.; LAWRENCE, David M.; ARTS, Peer; FENG, Jinghua; ANDREWS, James; ARMSTRONG, Mark; HA, Thuong; DOBBINS, Julia; DRAZER, Michael W.; YU, Kai; BODOR, Csaba; CANTOR, Alan; CAZZOLA, Mario; DEGELMAN, Erin; DINARDO, Courtney D.; DUPLOYEZ, Nicolas; FAVIER, Remi; FROHLING, Stefan; FITZGIBBON, Jude; KLCO, Jeffery M.; KRAMER, Alwin; KUROKAWA, Mineo; LEE, Joanne; MALCOVATI, Luca; MORGAN, Neil V.; NATSOULIS, Georges; OWEN, Carolyn; PATEL, Keyur P.; PREUDHOMME, Claude; RASLOVA, Hana; RIENHOFF, Hugh; RIPPERGER, Tim; SCHULTE, Rachael; TAWANA, Kiran; VELLOSO, Elvira; YAN, Benedict; LIU, Paul; GODLEY, Lucy A.; SCHREIBER, Andreas W.; HAHN, Christopher N.; SCOTT, Hamish S.; BROWN, Anna L.
- Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome(2021) SILVA, Marcela Cavalcante de Andrade; KATSUMURA, Koichi R.; MEHTA, Charu; VELLOSO, Elvira D. R. P.; BRESNICK, Emery H.; GODLEY, Lucy A.
bookPart O hemograma(2021) VELLOSO, Elvira D. R. P.; OTSUKA, Liliana Mitie Suganuma; PENTEADO, Rosana M. CosentinobookPart Aids: manifestações hematológicas e oncológicas relacionadas(2021) VELLOSO, Elvira Deolinda Rodrigues Pereira; PRACCHIA, Luis Fernando; SILVA JUNIOR, Wellington Fernandes da